NASDAQ:RNXT RenovoRx Q4 2024 Earnings Results & Report $1.04 -0.08 (-7.14%) As of 02:54 PM Eastern This is a fair market value price provided by Massive. Learn more. RenovoRx missed analyst expectations on both earnings and revenue in its Q4 2024 results, released March 31, 2025. The company reported EPS of -$0.13 versus the -$0.12 consensus estimate, while revenue of $40 thousand fell short of the $168 thousand estimate by $128 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2024Report DateMarch 31, 2025TimeBefore Market OpensConference Call DateApril 1, 2025Conference Call8:30 AM ET RenovoRx EPS ResultsActual EPS-$0.13Consensus EPS -$0.12Beat/MissMissed by -$0.01One Year Ago EPSN/AEPS Beat Rate1 of last 8 quartersRenovoRx Revenue ResultsActual Revenue$40 thousandExpected Revenue$168 thousandBeat/MissMissed by -$128.00 thousandYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) RenovoRx Q4 2024 Earnings FAQ Did RenovoRx beat earnings estimates for Q4 2024? RenovoRx (NASDAQ:RNXT) reported earnings of -$0.13 per share for Q4 2024, missing the consensus estimate of -$0.12. The report was announced on Monday, March 31, 2025. What was RenovoRx's revenue for Q4 2024? RenovoRx reported revenue of $40 thousand for Q4 2024, against a consensus estimate of $168 thousand. RenovoRx Earnings HeadlinesAnalysts Offer Insights on Healthcare Companies: RenovoRx (RNXT) and Eledon Pharmaceuticals (ELDN)2 hours ago | theglobeandmail.comRenovoRx Appoints Interventional Oncology Medtech Leader Richard Stark to its Board of DirectorsNovember 19 at 8:30 AM | globenewswire.comYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.November 19 at 1:00 AM | Reagan Gold Group (Ad)Brokers Issue Forecasts for RenovoRx Q1 EarningsNovember 14, 2026 | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: RenovoRx (RNXT) and Zimmer Biomet Holdings (ZBH)November 12, 2026 | theglobeandmail.comHC Wainwright Issues Negative Outlook for RenovoRx EarningsNovember 12, 2026 | americanbankingnews.comSee More RenovoRx Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like RenovoRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on RenovoRx and other key companies, straight to your email. Email Address About RenovoRxRenovoRx (NASDAQ:RNXT) is a clinical-stage biopharmaceutical company developing treatments for solid tumors. Its approach is designed to deliver therapy directly to targeted tissue through the arteries that supply it, with the goal of limiting exposure to the rest of the body. The company’s platform includes RenovoCath, a catheter cleared by the U.S. Food and Drug Administration for the localized infusion of therapeutic agents. RenovoRx is also evaluating RenovoGem, a combination of its delivery approach and the chemotherapy drug gemcitabine, for patients with locally advanced pancreatic cancer. RenovoRx is based in Mountain View, California. Its clinical development program includes the TIGeR-PaC study, which is evaluating its treatment approach in pancreatic cancer.View RenovoRx ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting GameWalmart Earnings Change the Narrative as Digital Growth Lifts OutlookWhatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play ItLowe's Earnings Beat Looked Strong Until a 34-Cent Tariff Refund Changed the MathApple's Next Margin Defense Could Be Hiding in Your WalletThe Uranium Price Paradox: 5 Investments Facing Very Different Tests in 2027Target Stock Is Up Over 70%—Has the Easy Money Already Been Made? Upcoming Earnings Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026)Dell Technologies (11/24/2026)Deere & Company (11/25/2026)CrowdStrike (12/1/2026)Marvell Technology (12/1/2026)Bank Of Montreal (12/2/2026)Bank of Nova Scotia (12/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.